AstraZeneca

AstraZeneca was incorporated in 1999 and has established its global headquarters in Cambridge, United Kingdom. The company operates primarily in five main business segments: Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, Other Medicines (including Infection, Neuroscience, and Gastrointestinal), and a dedicated COVID-19 category that gained prominence during the pandemic following the development of a COVID-19 vaccine. Notable brands under AstraZeneca's portfolio include Tagrisso for non-small cell lung cancer, Lynparza for various types of cancer including ovarian and breast, Imfinzi for bladder and lung cancers, the cholesterol-lowering Crestor, Symbicort for asthma and COPD, Farxiga for type 2 diabetes, heart failure, and chronic kidney disease, and Vaxzevria, the COVID-19 vaccine developed alongside the University of Oxford. The company has a significant global presence, with a product distribution network that spans Europe, the Americas, Asia, Africa, and the Middle East. Within these regions, AstraZeneca places a particular focus on markets with considerable size and healthcare expenditures – namely the United States, China, Japan, Germany, and the UK. (Powered by AI)